Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,956
  • Shares Outstanding, K 1,054
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,980 K
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow 0.15
  • Price/Book 0.29
Trade ENVB with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 297.47%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,243.59% on 05/12/22
  • IV Low 0.00% on 08/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,271
  • Open Int (30-Day) 1,261

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.90 +14.83%
on 07/28/22
14.87 -54.44%
on 08/03/22
-1.18 (-14.89%)
since 07/15/22
3-Month
5.90 +14.83%
on 07/28/22
18.50 -63.38%
on 07/11/22
-3.47 (-33.87%)
since 05/16/22
52-Week
5.90 +14.83%
on 07/28/22
187.00 -96.38%
on 09/10/21
-73.72 (-91.58%)
since 08/16/21

Most Recent Stories

More News
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant...

MMED.NE : 0.880 (-4.35%)
CYBN.NE : 0.970 (unch)
OPTI.CN : 0.375 (+5.63%)
OPTHF : 0.2859 (+3.96%)
ATAI : 4.77 (+1.92%)
MNMD : 0.6791 (-2.99%)
CYBN : 0.7700 (+1.49%)
ENVB : 6.91 (+4.70%)
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

/PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of...

OPTI.CN : 0.375 (+5.63%)
OPTHF : 0.2859 (+3.96%)
ATAI : 4.77 (+1.92%)
MNMD : 0.6791 (-2.99%)
CYBN : 0.7700 (+1.49%)
ENVB : 6.91 (+4.70%)
Enveric Biosciences Appoints New Independent Directors

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today...

ENVB : 6.91 (+4.70%)
Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today...

ENVB : 6.91 (+4.70%)
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today...

ENVB : 6.91 (+4.70%)
Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences , Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced...

ENVB : 6.91 (+4.70%)
Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today...

ENVB : 6.91 (+4.70%)
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed...

ENVB : 6.91 (+4.70%)
American Billionaire Entrepreneurs Bet Millions on Psychedelics

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman...

CYBN.NE : 0.970 (unch)
MYCO.NE : 0.770 (unch)
PYPL : 102.25 (+0.73%)
TSLA : 921.08 (-0.74%)
CYBN : 0.7700 (+1.49%)
MYCOF : 0.5800 (-15.94%)
NUMI.TO : 0.2950 (-3.28%)
NUMIF : 0.2324 (-2.19%)
ATAI : 4.77 (+1.92%)
ENVB : 6.91 (+4.70%)
Roth Capital Reveals Top Psychedelic Picks in New Industry Report

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report...

CYBN.NE : 0.970 (unch)
CYBN : 0.7700 (+1.49%)
ATAI : 4.77 (+1.92%)
EHVVF : 0.0075 (unch)
ENVB : 6.91 (+4.70%)
NUMI.TO : 0.2950 (-3.28%)
NUMIF : 0.2324 (-2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

See More

Key Turning Points

3rd Resistance Point 7.28
2nd Resistance Point 7.09
1st Resistance Point 6.84
Last Price 6.91
1st Support Level 6.40
2nd Support Level 6.21
3rd Support Level 5.96

See More

52-Week High 187.00
Fibonacci 61.8% 117.82
Fibonacci 50% 96.45
Fibonacci 38.2% 75.08
Last Price 6.91
52-Week Low 5.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar